Assignee
CELLECTAR BIOSCIENCES INC
US·7 granted patents·3 pending applications·27 citations·filing 2015–2020
Top patents by PatentIndex Score
10 records- 0194US9480754B2Phospholipid ether analogs as cancer-targeting drug vehiclesCELLECTAR BIOSCIENCES INC·Filed 2016·Granted Nov 1, 2016·11 cites·3 claims
- 0294US9345718B1Phospholipid ether analogs as cancer-targeting drug vehiclesCELLECTAR BIOSCIENCES INC·Filed 2015·Granted May 24, 2016·12 cites·2 claims
- 0389US9925269B2Phospholipid ether analogs as cancer-targeting drug vehiclesCELLECTAR BIOSCIENCES INC·Filed 2015·Granted Mar 27, 2018·4 cites·9 claims
- 0467US11439709B2Phospholipid ether analogs as cancer-targeting drug vehiclesCELLECTAR BIOSCIENCES INC·Filed 2018·Granted Sep 13, 2022·0 cites·11 claims
- 0549US11467159B2Luminescent phospholipid analogs for the identification and isolation of circulating tumor cellsCELLECTAR BIOSCIENCES INC·Filed 2017·Granted Oct 11, 2022·0 cites·8 claims
- 0647US2023066517A1Phospholipid Ether Conjugates as Cancer-Targeting Drug VehiclesCELLECTAR BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 0745US12496346B2Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapyCELLECTAR BIOSCIENCES INC·Filed 2020·Granted Dec 16, 2025·0 cites·12 claims
- 0837US12503479B2Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapyCELLECTAR BIOSCIENCES INC·Filed 2019·Granted Dec 23, 2025·0 cites·12 claims
- 0937US2024131204A1Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of CancerCELLECTAR BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 1030US2021106700A1Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of CancerCELLECTAR BIOSCIENCES INC·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →